BIOMARIN PHARMACEUTICAL INC (BMRN) earnings date
Feb 22, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 34 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 2, 2026 | after close | 33 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Mon, May 4, 2026 | after close | 34 | 8-K |
| Q4 FY2025 | Mon, Feb 23, 2026 | after close | 54 | 8-K |
| Q3 FY2025 | Mon, Oct 27, 2025 | after close | 27 | 8-K |
| Q2 FY2025 | Mon, Aug 4, 2025 | after close | 35 | 8-K |
| Q1 FY2025 | Thu, May 1, 2025 | after close | 31 | 8-K |
| Q4 FY2024 | Wed, Feb 19, 2025 | after close | 50 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Third Quarter 2026 Financial and Operating Results Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact of Two Acquired In-process Research and Development (IPR&D) Charges Recently Announced the Addition of a New Inves" exhibit |
| Q3 FY2026 | "The Phase 1/2a study in healthy volunteers and adults with HPP is ongoing, with data expected in 2027." exhibit |
| Q3 FY2026 | "The Phase 3 ACTION 3 trial is fully enrolled, with pivotal data expected in 2028." exhibit |
| Q3 FY2026 | "Dose-response data from this study is expected in 2027." exhibit |
| Q3 FY2026 | "More than 75% of VOXZOGO revenue was generated outside of the U.S., and a large international order previously expected in the third quarter is now anticipated in the fourth quarter." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Second Quarter 2026 Financial and Operating Results Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO ® , and Non-GAAP Diluted Earnings Per Share (EPS) Addition of GALAFOLD ® and POMBILITI ® + OPFOLDA ® , with Cost Synergies, Expected to Accelerate Revenue Growth, Non-GAAP Diluted EPS Accre" exhibit |
| Q2 FY2026 | "“Strong global demand led us to increase full-year VOXZOGO revenue guidance to at least $1 billion in 2026." exhibit |
| Q2 FY2026 | "We expect strong execution through the remainder of 2026, bringing together our expanded portfolio, scale and disciplined integration efforts to reach more patients living with serious genetic conditions around the world.” 2026 Business and Pipeline Highlights Innovation" exhibit |
| Q2 FY2026 | "The Phase 2/3 study is enrolling, with a data update expected in 2027." exhibit |
| Q2 FY2026 | "The Phase 3 ACTION 3 trial is ongoing, with pivotal data expected in 2028." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/BMRN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/BMRN
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/BMRN/"><img src="https://veritasdata.dev/embed/BMRN.svg" alt="BMRN earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/BMRN/)
Script
<script async src="https://veritasdata.dev/embed/BMRN.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/BMRN"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.